N/A
Completed N=6
Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)
Healthy Adult Volunteers
Source: ClinicalTrials.gov NCT01672242 ↗
Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcomePrimary: Change in End-expiratory Lung Volume — -144; 103 mL
Summary
Respiratory distress is a common problem in an intensive care unit. There are multiple mechanisms that are used to help patients who are in respiratory distress including mechanical ventilation, continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), high flow oxygen, and oxygen supplementation through nasal cannula or a facemask.
The purpose of this study is to evaluate the mechanism by which Vapotherm, a high flow oxygen system, provides breathing support. Vapotherm provides high flow oxygen at different flow rates, meaning one can increase the amount of oxygen flow to help with breathing support. The investigators believe that this high flow oxygen system may provide similar breathing support that a continuous positive airway pressure machine (CPAP) machine does.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in End-expiratory Lung Volume |
-144; 103 | — |
Eligibility Criteria
Inclusion Criteria
- Age between 18 and 75
- Able to follow and understand simple instructions to collect spirometry
Exclusion Criteria
- Younger than 18y/o
- Older than 75 years old
- History of chronic obstructive pulmonary disease (COPD)
- History of asthma
- History of congestive heart failure
- Measured ratio of forced expiratory volume at 1 second/forced vital capacity (FEV1/FVC) <70 when undergoing spirometry
Data sourced from ClinicalTrials.gov (NCT01672242). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.